Fluorescent bile salt derivatives such as cholyl-L-lysyl-fluorescein have shown diagnostic potential to evaluate biliary elimination. The invention relates to the development of a novel competitive Enzyme-linked immunosorbent assay (ELISA) assay to quantify fluorescent bile salt derivatives for the evaluation of drug-drug interactions and for diagnostic applications.